Stay updated on Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage related to a study of Pembrolizumab with Carboplatin and Gemcitabine in patients with metastatic triple negative breast cancer has been updated from 2023 to 2024 dates, indicating a change in the study timeline or status. This change may reflect an adjustment in the estimated completion date or enrollment period for the clinical trial.
    Difference
    1%
    Check dated 2024-06-06T14:19:17.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for clinical research participation.
    Difference
    64%
    Check dated 2024-05-22T20:56:24.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:51:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Triple Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Triple Negative Breast Cancer Clinical Trial page.